Regulators will review data on satri-cel's ability to treat advanced Claudin18.2-positive tumors in an expedited timeline.

The firm will use the proceeds from the private placement to advance its clinical-stage cardiomyopathy gene therapy programs.

The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11in the US market following approval.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed ...

Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.